Correlation Between Verve Therapeutics and Veracyte

Can any of the company-specific risk be diversified away by investing in both Verve Therapeutics and Veracyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Verve Therapeutics and Veracyte into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Verve Therapeutics and Veracyte, you can compare the effects of market volatilities on Verve Therapeutics and Veracyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Verve Therapeutics with a short position of Veracyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Verve Therapeutics and Veracyte.

Diversification Opportunities for Verve Therapeutics and Veracyte

-0.54

Correlation Coefficient

Verve Therapeutics  Veracyte

Excellent diversification

The 3 months correlation between Verve and Veracyte is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding Verve Therapeutics and Veracyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Veracyte and Verve Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Verve Therapeutics are associated (or correlated) with Veracyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Veracyte has no effect on the direction of Verve Therapeutics i.e., Verve Therapeutics and Veracyte go up and down completely randomly.

Pair Corralation between Verve Therapeutics and Veracyte

Given the investment horizon of 90 days Verve Therapeutics is expected to under-perform the Veracyte. In addition to that, Verve Therapeutics is 1.5 times more volatile than Veracyte. It trades about -0.04 of its total potential returns per unit of risk. Veracyte is currently generating about 0.06 per unit of volatility. If you would invest  1,591  in Veracyte on July 3, 2024 and sell it today you would earn a total of  1,813  from holding Veracyte or generate 113.95% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Verve Therapeutics  vs.  Veracyte

Verve Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Verve Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Verve Therapeutics is not utilizing all of its potentials. The newest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Veracyte

Risk-Adjusted Performance

14 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Veracyte are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Veracyte unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Verve Therapeutics and Veracyte

The main advantage of trading using opposite Verve Therapeutics and Veracyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Verve Therapeutics position performs unexpectedly, Veracyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Veracyte will offset losses from the drop in Veracyte's long position.

The idea behind Verve Therapeutics and Veracyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.